A Phase 4 interventional study of Suzetrigine and Placebo in Pelvic Organ Prolapse (POP), Postoperative Pain and Urogynecology, sponsored by Aditi Talkad. Not yet recruiting at 1 site in United States. Open to female participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Aditi Talkad · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 195 studies in Pelvic Organ Prolapse with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Pelvic Organ Prolapse · United States.
Among the 195 studies in Pelvic Organ Prolapse with a site in United States, this one is the 102nd largest by planned enrollment of the 133 interventional ones that give a count, is one of 5 that started in 2026, is one of 25 in phase 4, reaches primary completion later than 19 of the 22 other live ones, and was the 195th registered.
522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.
Browse Pelvic Organ Prolapse studies →12 of the 195 studies in Pelvic Organ Prolapse with a site in United States are open now. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 18+ · Women only
Cassandra Kisby · Sites in United States
Ages 21+ · Women only
The Cleveland Clinic · Sites in United States
Ages 18+
NICHD Pelvic Floor Disorders Network · Sites in United States
Ages 18–99 · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 53 Pelvic Organ Prolapse studies recruiting now, 31 (58%) set no upper age limit and 10 (19%) stop at 75 or younger; 2 take children under 18; 14 take healthy volunteers.
This study: 40 Years to 80 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
195 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 9 · Phase 4 25
First in 1996; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 80 across 337 interventional studies indexed under Pelvic Organ Prolapse.
Median enrollment 78 across the 133 interventional studies, 103 across the 61 observational. Of the 154 that completed or were terminated, 51 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 195 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Aditi Talkad as lead sponsor.
Aditi Talkad has 1 study filed under Pelvic Organ Prolapse — fewer than ten, so there is no comparison to draw.
8 of the studies in Pelvic Organ Prolapse with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04179955Mayo ClinicIntraoperative Costs and Patient Perceptions in Sacrocolpopexy for Prolapse | 2026-12 |
| NCT06634459Medstar Health Research InstitutePOMEGRANATE Trial: Comparing Reia Pessary Versus Standard of Care Pessary for Pelvic Organ Prolapse Treatment | 2027-01 |
| NCT07008898University of Alabama at BirminghamSequence of Midurethral Sling Placement During Robotic Sacrocolpopexy | 2027-05 |
| NCT07692789Ohio State UniversityImproving Uroflowmetry Interpretability: Evaluating the Impact of Patient Reminder Systems | 2027-06 |
| NCT07218016NICHD Pelvic Floor Disorders NetworkAccelerometer Measured Early Recovery After Prolapse Surgery | 2027-06-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 195 studies in Pelvic Organ Prolapse with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine whether suzetrigine, when added to standardized multimodal postoperative analgesia improves pain control and reduces opioid consumption after apical suspension surgery for pelvic organ prolapse.
Researchers will compare suzetrigine to a placebo (a look-alike substance that contains no drug) to evaluate this outcome.
The main questions it aims to answer are:
Researchers will compare participants receiving suzetrigine to participants receiving placebo, both on top of standard postoperative pain management, to see if suzetrigine lowers pain scores and opioid consumption after apical suspension surgery.
Suzetrigine is a first-in-class, selective NaV1.8 inhibitor that provides peripheral analgesia without opioid-related CNS effects. It was approved by the FDA in 2025 as a non-opioid alternative for moderate-to-severe pain following Phase 3 studies in abdominoplasty and bunionectomy. This single-center, randomized, double-blinded, placebo-controlled trial evaluates whether a suzetrigine-based postoperative analgesic regimen reduces opioid consumption and improves pain control compared with standard opioid-inclusive care following apical suspension surgery for pelvic organ prolapse. The study will enroll participants in a 1:1 ratio and assess pain, opioid consumption, adverse events, and patient-reported recovery over 7 days postoperatively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Undergoing major urogynecologic surgery, defined as having at least one of the following:
Exclusion Criteria:
Current narcotic use defined as daily use for more than 7 consecutive days in the 3 months prior to surgery, or current treatment for opioid use disorder.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive suzetrigine 100 mg (2 tablets) as a loading dose on the evening of surgery, followed by 50 mg every 12 hours for 7 days, in addition to standard multimodal analgesia. Standard analgesia consists of ibuprofen 600 mg every 6 hours and acetaminophen 650 mg every 6 hours, scheduled for the first 48 hours postoperatively, after which patients may transition to as-needed dosing of both. An opioid prescription will be sent if triggered by previously set score and based on the patient's reported pain score.
Drug: Suzetrigine
Participants will receive matching placebo as a loading dose (2 tablets) on the evening of surgery, followed by 1 tablet every 12 hours for 7 days, in addition to standard multimodal analgesia. Standard analgesia consists of ibuprofen 600 mg every 6 hours and acetaminophen 650 mg every 6 hours, scheduled for the first 48 hours postoperatively, after which patients may transition to as-needed dosing of both. An opioid prescription will be sent if triggered by the patient's reported pain score.
Drug: Placebo
Suzetrigine (JOURNAVX), an oral, first-in-class, selective NaV1.8 inhibitor, administered as a 100 mg (2-tablet) loading dose on the evening of surgery, followed by 50 mg every 12 hours for 7 days, in addition to standard postoperative multimodal analgesia (scheduled ibuprofen and acetaminophen for the first 48 hours). Suzetrigine is FDA-approved for moderate-to-severe acute pain and provides peripheral analgesia without opioid-related CNS effects.
Also known as: Experimental Group
Placebo, matched in appearance to suzetrigine and formulated by the site's investigational pharmacy, administered as a 2-tablet loading dose on the evening of surgery, followed by 1 tablet every 12 hours for 7 days, in addition to standard postoperative multimodal analgesia (scheduled ibuprofen and acetaminophen for the first 48 hours).
Also known as: Control Group
Postoperative Pain Score
Postoperative pain will be assessed using the Visual Analog Scale with change from baseline compared between patients receiving adjunctive suzetrigine versus standard multimodal postoperative pain management alone. This will assessed on a daily survey postoperatively.
Time frame: Baseline (preoperative) to 7 days postoperatively
Cumulative Postoperative Opioid Consumption
Total opioid consumption, measured in morphine milligram equivalents (MME), will be assessed via daily patient-reported surveys collected through postoperative day 7 and compared between patients receiving suzetrigine versus placebo groups.
Time frame: 7 days postoperatively
Patient-Reported Outcomes and Satisfaction With Postoperative Recovery
Patient-perceived control over pain management will be assessed using selected items from the American Pain Society Patient Outcome Questionnaire-Revised (APS-POQ-R), adapted for outpatient use following discharge.
Time frame: 7 days postoperatively
Treatment Tolerability
Treatment tolerability, including incidence of side effects, will be assessed via daily patient-reported surveys collected through postoperative day 7 and compared between patients receiving suzetrigine versus placebo.
Time frame: 7 days postoperatively
Plan to share: Undecided — A decision on individual participant data (IPD) sharing has not yet been finalized. This will be determined prior to study completion, pending institutional data-sharing policy review and consideration of participant privacy given the study's relatively small, single-site sample size.
Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suzetrigine